Sphere Fluidics has appointed Tris Vaughan to its scientific advisory board (SAB). Tris is vice president R&D antibody discovery and protein engineering for MedImmune, the global biologics research and development arm of AstraZeneca. He has held several key roles in MedImmune where he currently leads a team of 120 scientists. He has made a significant contribution to the discovery of several clinical candidates, and has authored numerous publications and patents. Prior to joining MedImmune, Tris was also a postdoctoral fellow at the University of Toronto and a graduate of the University of Leeds Genetics Department.
